models of care for the implementation of genomic medicine ukgtn commissioning workshop 22 nd ...
DESCRIPTION
Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012. Dr Trevor Cole Consultant and Honorary Reader in Clinical and Cancer Genetics West Midlands Regional Genetics Service Birmingham Womens Hospital [email protected]. NHS - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/1.jpg)
Models of care for the implementation of Genomic Medicine
UKGTN Commissioning Workshop
22nd November 2012
Dr Trevor ColeConsultant and Honorary Reader in
Clinical and Cancer GeneticsWest Midlands Regional Genetics
ServiceBirmingham Womens Hospital
![Page 2: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/2.jpg)
![Page 3: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/3.jpg)
Sub-committees to
identify educational
needs
Equitable delivery of high quality
integrated pathways
NHS ill-
prepared
www.geneticseducation.nhs.uk
![Page 4: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/4.jpg)
Patient management
Family management
Molecular test
![Page 5: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/5.jpg)
Management could mean :-• Diagnosis
• Patient Treatment (personalised medicine)
• Pre-symptomatic testing
• SurveillanceMaximise to obtain most clinical benefit and
utility
![Page 6: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/6.jpg)
Patient management
Family management
Molecular test
![Page 7: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/7.jpg)
What are we trying to achieve?
Patient Access
Diagnostic Process
Personalised
Medicine
![Page 8: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/8.jpg)
What are we trying to achieve?Optimisation of each of the Steps
Patient access
• Equal access
Diagnostic process
• Who• How• Consent
Personalised medicine
• Education of NHS
• Engagement with pharma and biotech
![Page 9: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/9.jpg)
What are we trying to achieve?Optimisation of each of the Steps and
Patient access
• Equal access
Diagnostic process
• How• Who• Consent
Personalised medicine
• Education of NHS
• Engagement with pharma and biotech
Extended family engagement where appropriate
![Page 10: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/10.jpg)
Access: success and failure
Retinoblastoma
Highly successful
Informed expert driven
Breast and Colon cancer
Quite successful
Patient driven and medical reactive
Common Disorders: Hypercholesterolaemia, Diabetes, Chronic Renal
failure
Much less successful
Why?
Less aware public and professions
![Page 11: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/11.jpg)
Access success – simple!! (If only)
• Educated and engaged public
• More aware profession and easier access to pathways (know when to refer)
• Commissioning process that encourages early intervention for the “well” – primary and secondary care
![Page 12: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/12.jpg)
Illustration of Diagnostic Process Deliberations and Consequences :- Is
it?• Marfan syndrome
• Rare aortopathy
• Homocysteinuria
![Page 13: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/13.jpg)
Making the Diagnosis of Marfan SyndromeClinical Molecular
For Against For AgainstIts cheap
In comfort zone
Still some benefit even if wrong aortopathy
I just saved £500!
Not made a definite diagnosis
Not recognised correct aortopathy
Life long follow up at risk
Precise diagnosis
Identify at risk relatives, or exclude.
Personalised medicine
Additional up-front expense
If wrong gene money down the drain!
No relatives in my area
Worried about consent and sharing confidential information
![Page 14: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/14.jpg)
How to encourage most appropriate diagnostic process :– make it part of a required pathway
• Homocysteinuria – urine adequate only if no other management issues
• Marfans – is a clinical diagnosis adequate to answer “all the other medical issues” to the benefit of “the whole NHS”
• Rare aortopathy – do I need to be aware of these alternative diagnoses and management issues
![Page 15: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/15.jpg)
Use SCN and NHSCB through CRG to :-
• Promote commissioning of MDT working
• Optimise pathway
• Support most appropriate clinical involvement (eg Marfans – expert cardiology, cardiothoracic surgeons, ophthalmology, clinical geneticists, nurse specialist/ genetic counsellors, orthopaedics, physiotherapy etc)
![Page 16: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/16.jpg)
What are we trying to achieve?Optimisation of each of the Steps and
Patient access
• Equal access
Diagnostic process
• How• Who• Consent
Personalised medicine
• Education of NHS
• Data collection
• Engagement with pharma and biotech
Extended family engagement where appropriate
![Page 17: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/17.jpg)
For “each patient” MDT discussion or agreed protocols to consider appropriate :-
• Diagnosis (What do I need to achieve 2 &3)
• Management• Genetic Cascade
• “premium for care” in “quality assured pathways” to cover initial expenses but to ensure downstream benefits (central to UKGTN gene dossiers – link from NLMC)
![Page 18: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/18.jpg)
Engagement of Public and Professionals(Requirement of the quality assured
pathway)• HGSG – importance of engagement and
education • GMC – medical school requirement• Royal Colleges and NMC – JCMG report• HEE – ensure part of the “CPD curriculum”
for LETB’s – remove the “unknown unknowns”
• Member of NCB with remit to genomics and promotion of education across the NHS
• Commissioners only support “QAP”
![Page 19: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/19.jpg)
Encourage engagement of Pharma and Biotechnology
• Smaller number of collaborators for more patients enrolled
• More consistent cohorts
• More consistent evaluations
• More cost effective research
![Page 20: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/20.jpg)
More consistency of consent
• More consistency of consent process• Increased awareness of equivocal results
and interpretation• Greater support for interpretation of
equivocal results• Greater emphasis on sharing information
for knowledge and family management as norm rather than exception or retrospective
![Page 21: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/21.jpg)
Should not be “a charter for ivory towers” practice : Criteria should be QAP delivery
• Rare is common – 3 million people in England have a rare disorder.
• 80% genetic • Many multisystemBut many • Common enough to be managed in many
centres (1 versus >1 per “sector”)• Need a lot of local support and input –
horizontal integrated care with IT systems to share relevant data and protocol management
![Page 22: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/22.jpg)
Inherited cardiacdisease
Led by clinical genetics
Cancer genetics Led by clinical genetics with pathways integrated into primary and secondary care
Neurogenetics Provided from within neurology
Endocrine geneticsService
Led by endocrinology with integrated clinical genetics
Familialhypercholesterolaemia
Structured multidisciplinary pathway led by lipid clinic clinicians with family cascade service hosted by regional genetics service
Single gene diabetes Led by diabetology with network of specialist nurses
![Page 23: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/23.jpg)
Patient access
• Equal access
Diagnostic process
• How• Who• Consent
Personalised medicine• Education of NHS
• Engagement with pharma and biotech
Extended family engagement where appropriate
Inherited cardiac disease Led by clinical genetics
Cancer genetics Led by clinical genetics with pathways integrated into primary and secondary care
Neurogenetics Provided from within neurology
Endocrine Genetics Service Led by endocrinology with integrated clinical genetics
Familial Hypercholesterolaemia Structured multidisciplinary pathway led by lipid clinic clinicians with family cascade service hosted by regional genetics service
Single gene diabetes Led by diabetology with network of specialist nurses
![Page 24: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/24.jpg)
Unexplained cardiac collapse
Cardio-myopathy
Myocardial infarct
Aortopathy
Conduction disorder
SmokingObesity
CholesterolDiabetes
Hypertension
Obesity (Leptin)Cholesterol (FH)
Diabetes (MODY)
Hypertension (GRBP)
DrugsMetabolic
AlcoholDrugsViral
AgeHypertensio
nSmoking
MarfansEhlers Danlos
Non Syndromic familial
aortopathies
HOCM, Fabry Disease
DMDHaemochromato
sis
LQT / Channelopathies
MetabolicMyotonic Dystrophy
Non Geneitc
Genetic
![Page 25: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/25.jpg)
Geleophysic – Acromicric DysplasiaNeed to overcome - “Who pays for the
test?”• Geleophysic – AR due to mutations in
ADAMTLS2 gene• Geleophysic/Acromicric – AD due to
mutations in the fibrillin gene• Prognosis differs across spectrum• Fibrillin mutation disorders show
evidence of response to anti TGF therapy
• Recurrence risk 1 in 2, 1 in 4 or very low
![Page 26: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/26.jpg)
Multiple Endocrine Neoplasia type 2 (MEN 2)• MEN 2A MTC
PhaeochromocytomaHyperparathyroidism
• MEN 2B MTCPhaeochromocytomaMarfanoid habitusMucosal neuromaGanglioneuromatosis gut
• Familial MTC ≥4 MTC No phaeochromocytoma No hyperparathyroidism
![Page 27: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/27.jpg)
Joint MTC at QEH
19 apparently sporadic MTC presenting to QEH over 2 years A mutation was identified in 3/19 (15.8%)
V804M heterozygous 43y maleV804M homozygous 54y femaleC618S heterozygous 30y female
Subsequent cascade testing in at risk family members
• → 18 predictive genetic tests → 13 positive→ 11 prophylactic thyroidectomies
![Page 28: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/28.jpg)
Joint MTC at QEH Histology at prophylactic surgeryNon neoplastic CCH 1Borderline CCH 1CCH 3MTC 5Await histology 1
• MTC identified in 5 /11 (~45.5%) at prophylactic surgeryC618S family V804M families53y female 65y female40y female36y female29y female
![Page 29: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/29.jpg)
Indications for using DNA testing :-
genetic management• Cascade screening• Prevention of unnecessary intervention• Appropriate surveillance for at risk
individuals• Is presymptomatic diagnosis and
intervention going to change the outcome?
• Does knowing the genetic basis change the management – (Germline) Warfarin dosage, PARP inhibitors, PTC124. (Somatic - oncology) Herceptin, Gleevac and Iressa
![Page 30: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/30.jpg)
Common Disease with a Major Genetic Component
• Renal Failure• Heart Disease• Hypertension• Osteoporosis• Diabetes Melitus• Most Types of Cancer
• All can be single gene or multifactorial
• All amenable to intervention
• Surveillance is often very simple
• Genetic testing maybe difficult and expensive
• Taking a family history is very easy and cheap!
• Some genetic testing is very beneficial
![Page 31: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/31.jpg)
Indications for genetic testingor
(How to persuade your commissioners!)
• Diagnosis (avoidance of unnecessary investigations)
• Management (most appropriate follow up and treatment)
• Genetic follow up (identification of gene carriers and exclusion of population risk follow up)
• Ensure you get the maximum clinical utility from you test (a no brainer???)
![Page 32: Models of care for the implementation of Genomic Medicine UKGTN Commissioning Workshop 22 nd November 2012](https://reader035.vdocument.in/reader035/viewer/2022070501/56816921550346895de053cb/html5/thumbnails/32.jpg)